StocksFin Logo
Merck & Co., Inc.
Merck & Co., Inc. country of incorporation
|
https://www.merck.com
|
Mr. Kenneth Frazier
|
67,000 employees
NYSE | Healthcare | Drug Manufacturers—General
Novo Nordisk A/S
Novo Nordisk A/S country of incorporation
|
https://www.novonordisk.com
|
Mr. Lars Fruergaard Jrgensen
|
52,696 employees
NYSE | Healthcare | Biotechnology
Q322 reported Nov 3, 2022 Reporting Period
$14.96B 13.7% vs. Q321 Revenues Q322
73.7% -0.1% vs. Q321 Gross Profit Margin
21.71% -37.5% vs. Q321 Net Profit Margin
4.48B -6.7% vs. Q321 Free Cash Flow Q322
$1.28 -29.3% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
0.8%
Q322
Q322 reported Sep 30, 2022 Reporting Period
$45.57B 27.9% vs. Q321 Revenues Q322
84.2% 1.5% vs. Q321 Gross Profit Margin
31.61% -7.1% vs. Q321 Net Profit Margin
20.01B -6.9% vs. Q321 Free Cash Flow Q322
$6.37 20.4% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
0.8%
Q322
Ratios
As of
Sep 30, 2022
Dec 31, 2022
Quick Ratio
0.9
0.67
Current Ratio
1.46
0.89
Cash Ratio
0.48
0.1
Price to Book
4.91
23.85
Price to Sales
14.58
11.25
Price to Earnings
16.79
35.86